New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
09:14 EDTDRTXDurata Therapeutics price target raised to $22 from $19 at JMP Securities
JMP Securities increased its price target on Durata after the company priced its Dalvance drug at the higher end of the range expected by the firm. The firm reiterates an Outperform rating on Durata.
News For DRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.
October 10, 2014
13:45 EDTDRTXDurata Therapeutics announces new data for dalbavancin
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use